Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | How can clinicians treat oligoprogression in renal cell carcinoma?

Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, describes the concept of oligoprogression in renal cell carcinoma, and suggests that the optimal approach to managing oligoprogression involves continuing the primary systemic treatment and using local therapies, such as stereotactic body radiation therapy (SBRT), to target the progressing sites. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

We can define oligoprogression as a situation in which in the face of a destabilization or even a response in certain tumor sites there is a progression in a limited number of metastatic sites. The ideal way to deal with this situation is to continue again the backbone of systemic treatment and then treat with local treatments the sites of oligoprogression. Possibly the best way to do that is the use of SBRT, that is radiation therapy directed to these sites...

We can define oligoprogression as a situation in which in the face of a destabilization or even a response in certain tumor sites there is a progression in a limited number of metastatic sites. The ideal way to deal with this situation is to continue again the backbone of systemic treatment and then treat with local treatments the sites of oligoprogression. Possibly the best way to do that is the use of SBRT, that is radiation therapy directed to these sites.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...